Synta Pharmaceuticals (SNTA +2.8%) gains after saying a study of ganetespib, its lead drug...


Synta Pharmaceuticals (SNTA +2.8%) gains after saying a study of ganetespib, its lead drug candidate, showed positive results as a treatment for oncologic indications, including a reduced rate of ocular toxicity. SNTA's primary research focus is on treatments for severe conditions such as cancer and chronic inflammatory diseases.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs